Edward Keystone
Impact in
- Rheumatology top 0.01%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Hematology top 0.05%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 309
- Rheumatoid Arthritis Research and Therapies 293
- Systemic Lupus Erythematosus Research 103
- Hematology 139
- Autoimmune and Inflammatory Disorders Research 127
- Co-authors
- Paul Emery (29 shared papers)Mark C. Genovese (30 shared papers)Larry W. Moreland (6 shared papers)Michael Schiff (15 shared papers)Michael E. Weinblatt (18 shared papers)Steven Fischkoff (4 shared papers)Roy Fleischmann (21 shared papers)Elliot Chartash (3 shared papers)
- Journals
- Annals of the Rheumatic Diseases (98 papers)The Journal of Rheumatology (42 papers)Lara D. Veeken (23 papers)Arthritis Care & Research (15 papers)ACR Open Rheumatology (9 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Edward Keystone
390 papers receiving 23.5k citations
Edward Keystone's Hit Papers
Peers
Comparison fields: 5 of 149
- Rheumatology 17.0k
- Hematology 7.8k
- Genetics 4.2k
- Immunology 6.8k
- Pathology and Forensic Medicine 3.1k
Countries citing papers authored by Edward Keystone
This map shows the geographic impact of Edward Keystone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Keystone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Keystone more than expected).
Fields of papers citing papers by Edward Keystone
This network shows the impact of papers produced by Edward Keystone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Keystone. The network helps show where Edward Keystone may publish in the future.
Co-authors
The 25 scholars most cited alongside Edward Keystone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 404 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Hit paper breakdown → | 2003 | 1413 |
| 2 | A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis Hit paper breakdown → | 2000 | 1404 |
| 3 | Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks Hit paper breakdown → | 2006 | 1267 |
| 4 | Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial Hit paper breakdown → | 2004 | 956 |
| 5 | Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial Hit paper breakdown → | 2004 | 940 |
| 6 | IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Hit paper breakdown → | 2008 | 866 |
| 7 | Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis Hit paper breakdown → | 2017 | 621 |
| 8 | Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes Hit paper breakdown → | 2002 | 573 |
| 9 | Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Hit paper breakdown → | 2003 | 559 |
| 10 | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Hit paper breakdown → | 2005 | 502 |
| 11 | Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study Hit paper breakdown → | 2008 | 465 |
| 12 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Hit paper breakdown → | 2013 | 456 |
| 13 | Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Hit paper breakdown → | 2008 | 432 |
| 14 | 2006 | 342 | |
| 15 | 2002 | 322 | |
| 16 | 2011 | 317 | |
| 17 | 2006 | 296 | |
| 18 | 2012 | 283 | |
| 19 | 2008 | 278 | |
| 20 | 2012 | 264 |
About Edward Keystone
Edward Keystone is a scholar working on Rheumatology, Hematology, Genetics, Pathology and Forensic Medicine and Immunology, having authored 404 papers that have together received 24.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (293 papers), Autoimmune and Inflammatory Disorders Research (127 papers), Systemic Lupus Erythematosus Research (103 papers), Chronic Lymphocytic Leukemia Research (102 papers), Lymphoma Diagnosis and Treatment (87 papers), Monoclonal and Polyclonal Antibodies Research (45 papers), Biosimilars and Bioanalytical Methods (38 papers) and Pharmaceutical studies and practices (15 papers). The work is most often cited by research in Rheumatology (17.0k citations), Hematology (7.8k citations), Genetics (4.2k citations), Immunology (6.8k citations) and Pathology and Forensic Medicine (3.1k citations). Edward Keystone has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Paul Emery, Mark C. Genovese, Larry W. Moreland, Michael Schiff, Michael E. Weinblatt, Steven Fischkoff, Roy Fleischmann, Elliot Chartash, Joan M. Bathon and Désirée van der Heijde. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, Lara D. Veeken, Arthritis Care & Research and ACR Open Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.